Items where authors include "Denton, C.P."

Export as [feed] Atom [feed] RSS
Number of items: 14.

Article

Lescoat, A., Bellando-Randone, S., Campochiaro, C. et al. (9 more authors) (2023) Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine. The Lancet Rheumatology, 5 (11). e683-e694. ISSN 2665-9913

Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology, 62 (9). pp. 3133-3138. ISSN 1462-0324

Spiera, R. orcid.org/0000-0003-2911-6800, Kuwana, M. orcid.org/0000-0001-8352-6136, Khanna, D. orcid.org/0000-0003-1412-4453 et al. (28 more authors) (2023) Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 75 (9). pp. 1608-1618. ISSN 2326-5191

Lepri, G., Hughes, M., Allanore, Y. et al. (8 more authors) (2023) The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution. The Lancet Rheumatology, 5 (7). e422-e425. ISSN 2665-9913

Denton, C.P. orcid.org/0000-0003-3975-8938, De Lorenzis, E., Roblin, E. et al. (27 more authors) (2023) Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 7 (1). rkad022. ISSN 2514-1775

Denton, C.P. orcid.org/0000-0003-3975-8938, del Galdo, F. orcid.org/0000-0002-8528-2283, Khanna, D. et al. (12 more authors) (2023) Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 62 (1). pp. 234-242. ISSN 1462-0324

Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology. ISSN 1462-0324

Kakkar, V., Assassi, S., Allanore, Y. et al. (4 more authors) (2022) Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Current Opinion in Rheumatology, 34 (6). pp. 357-364. ISSN 1040-8711

Hughes, M., Allanore, Y., Baron, M. et al. (13 more authors) (2022) Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. The Lancet Rheumatology, 4 (11). e795-e803. ISSN 2665-9913

Lescoat, A., Murphy, S.L., Roofeh, D. et al. (17 more authors) (2020) Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 6 (1). 66 -76. ISSN 2397-1983

Bageghni, S.A., Hemmings, K.E., Yuldasheva, N.Y. et al. (11 more authors) (2019) Fibroblast-specific deletion of IL-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight, 4 (17). ISSN 2379-3708

Peytrignet, S., Denton, C.P., Lunt, M. et al. (60 more authors) (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 57 (2). pp. 370-381. ISSN 1462-0324

Herrick, A.L., Pan, X., Peytrignet, S. et al. (61 more authors) (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases. ISSN 0003-4967

Proceedings Paper

De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 733-734.

This list was generated on Sat Mar 23 13:42:06 2024 GMT.